Commodore Capital LP Viridian Therapeutics, Inc.\De Transaction History

Commodore Capital LP

$1.07 Billion
Q2 2025

A detailed history of Commodore Capital LP transactions in Viridian Therapeutics, Inc.\De stock. As of the latest transaction made, Commodore Capital LP holds 4,875,000 shares of VRDN stock, worth $87.6 Million. This represents 6.35% of its overall portfolio holdings.

Number of Shares

4,875,000

Previous 3,600,000 35.42%

Holding current value

$87.6 Million

Previous $48.5 Million 40.44%

% of portfolio

6.35%

Previous 4.75%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	BUY	$11.02 - $16.09 $14.1 Million - $20.5 Million	1,275,000 Added 35.42%	4,875,000 $68.2 Million
Q1 2025 May 15, 2025	BUY	$13.48 - $20.91 $16.2 Million - $25.1 Million	1,200,000 Added 50.0%	3,600,000 $48.5 Million
Q4 2024 Feb 14, 2025	SELL	$17.85 - $25.71 $2.68 Million - $3.86 Million	-150,124 Reduced 5.89%	2,400,000 $46 Million
Q3 2024 Nov 14, 2024	BUY	$12.16 - $23.33 $268,638 - $515,406	22,092 Added 0.87%	2,550,124 $58 Million
Q2 2024 Aug 14, 2024	BUY	$11.6 - $17.26 $6.88 Million - $10.2 Million	593,379 Added 30.67%	2,528,032 $32.9 Million
Q1 2024 May 15, 2024	BUY	$17.09 - $23.82 $180,795 - $251,991	10,579 Added 0.55%	1,934,653 $33.9 Million
Q4 2023 Feb 14, 2024	SELL	$11.12 - $22.5 $3.07 Million - $6.21 Million	-275,926 Reduced 12.54%	1,924,074 $41.9 Million
Q2 2023 Aug 14, 2023	BUY	$22.57 - $29.67 $233,396 - $306,817	10,341 Added 0.47%	2,200,000 $52.3 Million
Q1 2023 May 15, 2023	BUY	$25.04 - $37.6 $4.24 Million - $6.37 Million	169,493 Added 8.39%	2,189,659 $55.7 Million
Q4 2022 Feb 14, 2023	SELL	$18.78 - $29.74 $12.7 Million - $20.1 Million	-676,174 Reduced 25.08%	2,020,166 $59 Million
Q3 2022 Nov 14, 2022	BUY	$10.7 - $25.5 $11.3 Million - $27 Million	1,057,731 Added 64.55%	2,696,340 $55.3 Million
Q2 2022 Aug 15, 2022	BUY	$9.55 - $19.0 $6.56 Million - $13.1 Million	687,270 Added 72.24%	1,638,609 $19 Million
Q1 2022 May 16, 2022	BUY	$16.79 - $20.88 $1.74 Million - $2.16 Million	103,656 Added 12.23%	951,339 $17.6 Million
Q4 2021 Feb 14, 2022	BUY	$15.65 - $21.5 $2.82 Million - $3.87 Million	180,009 Added 26.96%	847,683 $16.8 Million
Q3 2021 Nov 15, 2021	BUY	$10.69 - $18.2 $5.14 Million - $8.76 Million	481,269 Added 258.18%	667,674 $11 Million
Q2 2021 Oct 14, 2021	SELL	$14.34 - $18.67 $2.58 Million - $3.36 Million	-180,009 Reduced 49.13%	186,405 $3.41 Million
Q2 2021 Aug 16, 2021	BUY	$14.34 - $18.67 $2.59 Million - $3.37 Million	180,633 Added 97.23%	366,414 $6.7 Million
Q1 2021 Oct 14, 2021	SELL	$15.5 - $24.93 $2.79 Million - $4.49 Million	-180,009 Reduced 49.21%	185,781 $3.1 Million
Q1 2021 May 17, 2021	BUY	$15.5 - $24.93 $5.67 Million - $9.12 Million	365,790 New	365,790 $6.11 Million

Others Institutions Holding VRDN

# of Institutions

184

Shares Held

82.7M

Call Options Held

78.9K

Put Options Held

417K

View Full List

About Viridian Therapeutics, Inc.\DE

Ticker VRDN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,888,900
Market Cap $717M
Description
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...

More about VRDN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Commodore Capital LP, based on Form 13F filings with the SEC.

News

Stay updated on Commodore Capital LP with notifications on news.

Account

Commodore Capital LP Viridian Therapeutics, Inc.\De Transaction History